Leading Research into Head & Neck Cancer

How can we avoid giving patients unnecessary treatment ‘as a precaution’ when treatment results are not clear?

Full project name: Mutation profiling of circulating tumour DNA to inform prognosis and treatment selection for head and neck cancers

Tag: Predictive tests

Predicative Tests
The problem

Currently, when patients with oropharyngeal cancer are treated with chemo-radiotherapy, 12 weeks after treatment they have a PET scan to check for the presence of any remaining cancer, called residual disease.

The scan shows how successful the patients response to treatment has been. If all clear, patients can enter surveillance. If there is still tumour remaining, further treatment such as neck dissection is required.

However, for a proportion of patients, there is some doubt around what the scan is showing. Is there cancer remaining or are they clear? In these cases, even though not all these patients will have residual disease, as a precaution all patients are offered further treatment which may or may not be necessary.

On the flip side, for a minority group, patients with scans that are thought to show no residual tumour, then return at 3 months with recurrence of the disease.

The research
The future
University of Oxford
University of Oxford
Prof Jenny Taylor
Prof Jenny Taylor

Project type:

Project Leader:

Dr Jenny Taylor

Commencement date:
December 2018

Length of project:
2 years

Funding provided:

Heads Up

University of Oxford

Help fund this project

For more information on funding this project specifically please email us

To support the costs across all our life-changing projects please click below to donate now

Follow us

Get in touch

Call 020 3875 8991

Email info@oraclecancertrust.org


Oracle Cancer Trust is a registered charity in England and Wales (1142037). A company limited by guarantee. Registered company in England and Wales (7125497). Registered address: 10 Parsons Green House, 27 Parsons Green Lane, London SW6 4HH.